Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC

article

Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC is …
instance of (P31):
scholarly articleQ13442814

External links are
P932PMC publication ID6172687
P698PubMed publication ID30014681

P50authorGabriela Abelenda AlonsoQ86643753
P2093author name stringM Cervero Jiménez
J J Jusdado Ruiz-Capillas
M D Corbacho Loarte
R Núñez Ramos
P2860cites workReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsQ24646677
Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health servicesQ30637715
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Q34478074
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremiaQ34783668
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysisQ35030135
Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC).Q35621251
Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.Q35676380
Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.Q35746096
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremiaQ35879117
Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infectionQ37114426
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremiaQ38127663
Risk Factors for 30-Day Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.Q38770051
Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia.Q39681835
Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated InfectionQ40200466
High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureusQ40263706
Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?Q40891194
Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapyQ42278213
Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan--SMART program, 2003.Q43162354
Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?Q43208168
Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong KongQ43229615
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibilityQ43433837
Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremiaQ44883937
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremiaQ46826194
Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus causing bacteraemia.Q47703908
Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patientsQ47811432
Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.Q54062872
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospitalQ74716023
Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infectionsQ78524086
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05Q80595494
Peripheral venous catheter-related Staphylococcus aureus bacteremiaQ84073130
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectStaphylococcus aureusQ188121
vancomycinQ424027
P304page(s)353-362
P577publication date2018-05-04
P1433published inRevista Española de QuimioterapiaQ20020560
P1476titleStaphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC
P478volume31